Cargando…

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk

The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway is a membrane-to-nucleus signaling cascade that effects activation of gene transcription. JAK inhibitors have demonstrated effectiveness in autoimmune diseases such as rheumatoid arthritis. An increased risk of in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajasimhan, Suraj, Pamuk, Omer, Katz, James D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387323/ https://www.ncbi.nlm.nih.gov/pubmed/32514874 http://dx.doi.org/10.1007/s40266-020-00775-w

Ejemplares similares

Authors’ Reply to Moura et al.: “Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk”
por: Rajasimhan, Suraj, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
por: van Leeuwen, Roelof W. F., et al.
Publicado: (2017)

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty
por: Arden, Nigel, et al.
Publicado: (2015)

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis
por: Bruyère, Olivier, et al.
Publicado: (2015)

Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
por: Charpiat, Bruno, et al.
Publicado: (2020)

A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials
por: Patera, Andriani C., et al.
Publicado: (2023)

Research into the Health Benefits of Sprint Interval Training Should Focus on Protocols with Fewer and Shorter Sprints
por: Vollaard, Niels B. J., et al.
Publicado: (2017)

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
por: Annemans, Lieven, et al.
Publicado: (2018)

Pushing boundaries of video review in trauma: using comprehensive data to improve the safety of trauma care
por: Nolan, Brodie, et al.
Publicado: (2020)

Artificial Intelligence and the Future of the Drug Safety Professional
por: Danysz, Karolina, et al.
Publicado: (2018)

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation
por: Kowey, Peter R., et al.
Publicado: (2012)

Assessing the Safety of COVID-19 Vaccines: A Primer
por: Petousis-Harris, Helen
Publicado: (2020)

Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many
por: Cadogan, Cathal A., et al.
Publicado: (2015)

Black Swan Events and Intelligent Automation for Routine Safety Surveillance
por: Kjoersvik, Oeystein, et al.
Publicado: (2022)

What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects
por: van Eekeren, Rike, et al.
Publicado: (2018)

Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
por: Pimentel, Franklin Fernandes, et al.
Publicado: (2018)

Frailty and Potentially Inappropriate Prescribing in Older People with Polypharmacy: A Bi-Directional Relationship?
por: Randles, Mary A., et al.
Publicado: (2022)

A Structured Methodology to Assess Safety Signal Strength and Inform Causality Assessment
por: Sullivan, Tim, et al.
Publicado: (2022)

Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
por: Mori, Shunsuke, et al.
Publicado: (2021)

Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
por: Smit, Cornelis, et al.
Publicado: (2020)

The Underrated Risks of Tamoxifen Drug Interactions
por: Hansten, Philip D.
Publicado: (2018)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
por: Atal, Shubham, et al.
Publicado: (2020)

MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19
por: Hum, Christine, et al.
Publicado: (2021)

The Patient’s Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization
por: Smith, Meredith Y., et al.
Publicado: (2016)

Safety of International Professional Sports Competitions During the COVID-19 Pandemic: The Association Football Experience
por: Caniza, Horacio, et al.
Publicado: (2022)

From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients
por: Koufakis, Theocharis, et al.
Publicado: (2022)

NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View
por: Angoulvant, Denis, et al.
Publicado: (2021)

Potential Risks of Pharmacy Compounding
por: Gudeman, Jennifer, et al.
Publicado: (2013)

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
por: Urban, Philip, et al.
Publicado: (2019)

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
por: Zhang, Juqi, et al.
Publicado: (2023)

Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction
por: Elserafy, Ahmed S., et al.
Publicado: (2021)

The Janus-Face of Bacteriophages across Human Body Habitats
por: Wahida, Adam, et al.
Publicado: (2016)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

Drug Exposure and the Risk of Microscopic Colitis: A Critical Update
por: Lucendo, Alfredo J.
Publicado: (2017)

Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients
por: Napoli, Claudio, et al.
Publicado: (2020)

Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
por: Bello, Alfonso E., et al.
Publicado: (2014)

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
por: Ference, Brian A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u2g5d32c089mhh0rs1942m237b